Based on the results of the Prospective Cardiovascular Miinster Study (PROCAM-Trial), new possibilities are shown which permit the recognition of a coronary risk or the prediction of the likelihood of amyocardial infarction. Practical problems in the classification oflipid metabolismdisordersare dis
Comparative account of serum lipids, lipoproteins and apolipoprotein-B in patients of coronary artery disease
β Scribed by Ritu Sharma; Mridula Mahajan; Ravi Kant
- Publisher
- Association of Clinical Biochemistry of India
- Year
- 2004
- Tongue
- English
- Weight
- 287 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0970-1915
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The effects of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in 37 patients with ischemic heart disease were examined in a randomized, multicenter study. Nicorandil (n = 20, 10-40 mg/day, b.i.d.) and diltiazem (n = 17, 60-240 mg/day, b.i.d.) were administered for 12
Background: Apolipoprotein (apo) E polymorphism plays a significant role in the development of coronary disease, but their involvement in coronary artery stenosis (CAS) is controversial. Therefore, the purpose of this study was to investigate the effects of this polymorphism on atherosclerosis, and
Non-insulin-dependent diabetes mellitus (NIDDM) is a strong and independent risk factor for cardiovascular and coronary heart disease mortality [1]. Established risk factors, including glucose intolerance, arterial hypertension, central obesity, hypercholesterolaemia or hypertriglyceridaemia, have b